The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction

被引:105
作者
McFadden, DC
De Jesus, M
Casadevall, A
机构
[1] Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
关键词
D O I
10.1074/jbc.M509465200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The most distinctive feature of the human pathogenic fungus is a polysaccharide capsule that is essential for virulence and is composed primarily of glucuronoxylomannan (GXM) and galactoxylomannan (GalXM). GXM mediates multiple deleterious effects on host immune function, yet relatively little is known about its physical properties. The average mass of Cryptococcus neoformans GXM from four antigenically different strains ranged from 1.7 to 7 x 10(6) daltons as calculated from Zimm plots of light-scattering data. GalXM was significantly smaller than GXM, with an average mass of 1 x 10(5) daltons. These molecular masses imply that GalXM is the most numerous polysaccharide in the capsule on a molar basis. The radius of gyration of the capsular polysaccharides ranged between 68 and 208 nm. Viscosity measurements suggest that neither polysaccharide altered fluid dynamics during infection since GXM behaved in solution as a polyelectrolyte and GalXM did not increase solution viscosity. Immunoblot analysis indicated heterogeneity within GXM. In agreement with this, scanning transmission electron microscopy of GXM preparations revealed a tangled network of two different types of molecules. Mass per length measurements from light scattering and scanning transmission electron microscopy were consistent and suggested GXM molecules self-associate. A mechanism for capsule growth is proposed based on the extracellular release and entanglement of GXM molecules.
引用
收藏
页码:1868 / 1875
页数:8
相关论文
共 66 条
[1]   Cavitating pneumonia after treatment with infliximab and prednisone [J].
Arend, SM ;
Kuijper, EJ ;
Allaart, CF ;
Muller, WH ;
van Dissel, JT .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (08) :638-641
[2]   Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans [J].
Bryan, RA ;
Zaragoza, O ;
Zhang, T ;
Ortiz, G ;
Casadevall, A ;
Dadachova, E .
EUKARYOTIC CELL, 2005, 4 (02) :465-475
[3]   MONOCLONAL-ANTIBODY BASED ELISAS FOR CRYPTOCOCCAL POLYSACCHARIDE [J].
CASADEVALL, A ;
MUKHERJEE, J ;
SCHARFF, MD .
JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 154 (01) :27-35
[4]   THE MOUSE ANTIBODY-RESPONSE TO INFECTION WITH CRYPTOCOCCUS-NEOFORMANS - VH AND VL USAGE IN POLYSACCHARIDE BINDING-ANTIBODIES [J].
CASADEVALL, A ;
SCHARFF, MD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (01) :151-160
[5]   ANTIBODIES ELICITED BY A CRYPTOCOCCUS-NEOFORMANS TETANUS TOXOID CONJUGATE VACCINE HAVE THE SAME SPECIFICITY AS THOSE ELICITED IN INFECTION [J].
CASADEVALL, A ;
MUKHERJEE, J ;
DEVI, SJN ;
SCHNEERSON, R ;
ROBBINS, JB ;
SCHARFF, MD .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (06) :1086-1093
[6]   Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier [J].
Charlier, C ;
Chrétien, F ;
Baudrimont, M ;
Mordelet, E ;
Lortholary, O ;
Dromer, F .
AMERICAN JOURNAL OF PATHOLOGY, 2005, 166 (02) :421-432
[7]  
Cherniak R, 1998, CLIN DIAGN LAB IMMUN, V5, P146
[8]   STRUCTURE DETERMINATION OF CRYPTOCOCCUS-NEOFORMANS SEROTYPE A-VARIANT GLUCURONOXYLOMANNAN BY C-13-NMR SPECTROSCOPY [J].
CHERNIAK, R ;
JONES, RG ;
REISS, E .
CARBOHYDRATE RESEARCH, 1988, 172 (01) :113-138
[9]   A GALACTOXYLOMANNAN ANTIGEN OF CRYPTOCOCCUS-NEOFORMANS SEROTYPE-A [J].
CHERNIAK, R ;
REISS, E ;
TURNER, SH .
CARBOHYDRATE RESEARCH, 1982, 103 (02) :239-250
[10]   PREVALENCE IN CRYPTOCOCCUS-NEOFORMANS STRAINS OF A POLYSACCHARIDE EPITOPE WHICH CAN ELICIT PROTECTIVE ANTIBODIES [J].
CLEARE, W ;
MUKHERJEE, S ;
SPITZER, ED ;
CASADEVALL, A .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1994, 1 (06) :737-740